Rxivist logo

A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential

By Junwei Gai, Linlin Ma, Guanghui Li, Min Zhu, Peng Qiao, Xiaofei Li, Haiwei Zhang, Yanmin Zhang, Yadong Chen, Weiwei Ji, Hao Zhang, Huanhuan Cao, Xionghui Li, Rui Gong, Yakun Wan

Posted 10 Aug 2020
bioRxiv DOI: 10.1101/2020.08.09.242867

The outbreak of COVID-19 has emerged as a global pandemic. The unprecedented scale and severity call for rapid development of effective prophylactics or therapeutics. We here reported Nanobody (Nb) phage display libraries derived from four camels immunized with the SARS-CoV-2 spike receptor-binding domain (RBD), from which 381 Nbs were identified to recognize SARS-CoV-2-RBD. Furthermore, seven Nbs were shown to block interaction of human angiotensin converting enzyme 2 (ACE2) with SARS-CoV-2-RBD-variants, bat-SL-CoV-WIV1-RBD and SARS-CoV-1-RBD. Among the seven candidates, Nb11-59 exhibited the highest activity against authentic SARS-CoV-2 with ND50 of 0.55 μg/mL. Nb11-59 can be produced on a large-scale in Pichia pastoris , with 20 g/L titer and 99.36% purity. It also showed good stability profile, and nebulization did not impact its stability. Overall, Nb11-59 might be a promising prophylactic and therapeutic molecule against COVID-19, especially through inhalation delivery. ![Figure][1]</img> ### Competing Interest Statement All commercial rights from this paper belong to Shanghai Novamab Biopharmaceuticals Co., Ltd. [1]: pending:yes

Download data

  • Downloaded 2,739 times
  • Download rankings, all-time:
    • Site-wide: 6,510
    • In bioengineering: 86
  • Year to date:
    • Site-wide: 13,094
  • Since beginning of last month:
    • Site-wide: 29,065

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide